┌──────────────────────────────────────────────────────────────┐
  RECORD TYPE ......... ANNOTATION — SOURCED RECORD
  REGISTRY NO. ........ MARG-0596
  SLUG ................ /martin-keller-study-329-role-statements
  STATUS .............. ACTIVE
  FILED ............... 2026-06-22 04:16 UTC
  LAST ANNOTATED ...... 2026-06-22 04:16 UTC
  CLAIMS ON FILE ...... 5
  MEAN TAG CONFIDENCE . 0.88
└──────────────────────────────────────────────────────────────┘
PENDINGAnnotated by ARGUS, Chief Annotator

Martin Keller's Role and Statements in Study 329 Paroxetine Trial

SUMMARY

Study 329 was a clinical trial conducted from 1994 to 1998 to evaluate the efficacy of paroxetine (Paxil/Seroxat), an SSRI antidepressant, for major depressive disorder in adolescents aged 12-18 [2, 6]. The trial was sponsored by SmithKline Beecham (later GlaxoSmithKline), which held the patent for paroxetine and sought to license the drug for pediatric use [6].

Martin B. Keller was the first author of the original 2001 publication from Study 329. This publication controversially concluded that paroxetine was "generally well tolerated and effective for major depression in adolescents," despite the study's underlying data reportedly showing negative efficacy and increased harm, including suicidality and emotional lability, for teenagers [4, 1]. Critics allege that the published article was ghostwritten and misrepresented the actual study findings to favor the sponsor's commercial interests [1, 4].

Keller's specific involvement in the ghostwriting process or any personal statements regarding publication pressures or restrictions remain publicly underexplored. He has reportedly not responded to messages seeking comment on the controversy surrounding Study 329 [8]. The original publication has since received an expression of concern due to ongoing criticism [8].

STRONGEST CASE FOR

Martin Keller, as the lead author, likely reviewed and approved the content of the Study 329 publication based on the data he was presented. While the published conclusion was positive, this might have been due to his interpretation of specific outcomes or a belief that the drug offered some benefit, even if not universally across all endpoints. The complexity of clinical trial data and statistical interpretation can lead to different conclusions, and Keller may have genuinely believed in the published findings at the time, operating within the standard practices for industry-sponsored research of that era. Without direct evidence of his complicity in fraud, assuming malicious intent over professional judgment or oversight is premature.

STRONGEST CASE AGAINST

The published conclusion that paroxetine was "generally well tolerated and effective" for adolescents directly contradicted the internal study data which reportedly showed negative efficacy and increased suicidality and emotional lability [4, 1]. This discrepancy suggests that the published article, for which Keller was the lead author, misrepresented the findings. The allegation of ghostwriting further implies that the article's positive spin was influenced by the sponsor, SmithKline Beecham, rather than being an independent academic assessment. As first author, Keller bore ultimate responsibility for the accuracy and integrity of the publication, and his failure to ensure this, especially given the significant harm potential for a vulnerable patient population, points to a severe lapse in professional and ethical conduct, whether due to direct involvement in misrepresentation or negligence.

CLAIMS

  1. VERIFIEDCONF 0.95

    Martin B. Keller was the first author of the original published article for Study 329.

    — attributed to: Retraction Watch, Wikipedia

    • https://en.wikipedia.org/wiki/Martin_Keller_(psychiatrist)
    • https://retractionwatch.com/2025/10/16/controversial-paxil-study-329-earns-expression-of-concern-after-critic-sues-publisher/
  2. VERIFIEDCONF 0.95

    Keller's article for Study 329 concluded that paroxetine was "generally well tolerated and effective for major depression in adolescents."

    — attributed to: Wikipedia

    • https://en.wikipedia.org/wiki/Martin_Keller_(psychiatrist)
  3. CORROBORATEDCONF 0.90

    Study 329's underlying data indicated negative efficacy and increased suicidality and emotional lability for teenagers, contradicting the published conclusion.

    — attributed to: Wikipedia, ResearchGate, critics of Study 329

    • https://en.wikipedia.org/wiki/Martin_Keller_(psychiatrist)
    • https://www.researchgate.net/publication/23258838_Industry-Sponsored_Ghostwriting_in_Clinical_Trial_Reporting_A_Case_Study
  4. CORROBORATEDCONF 0.80

    The publication of Study 329 was ghostwritten.

    — attributed to: ResearchGate article, critics of Study 329

    • https://www.researchgate.net/publication/23258838_Industry-Sponsored_Ghostwriting_in_Clinical_Trial_Reporting_A_Case_Study
  5. SINGLE-SOURCECONF 0.80

    Martin Keller has not returned messages seeking comment regarding the controversy surrounding Study 329.

    — attributed to: Retraction Watch

    • https://retractionwatch.com/2025/10/16/controversial-paxil-study-329-earns-expression-of-concern-after-critic-sues-publisher/

TIMELINE

  • 1994Study 329 clinical trial began in North America. [src]
  • 1998Study 329 clinical trial concluded. [src]
  • 2001Original publication of Study 329, with Martin B. Keller as first author, concluding positive efficacy and tolerability for paroxetine in adolescents. [src]
  • 2025-10-16Retraction Watch reports an 'expression of concern' for the controversial Study 329 paper after a critic sues the publisher. [src]

ENTITIES

  • PERSON Martin B. Keller — First author of Study 329 publication, Professor Emeritus of Psychiatry and Human Behavior at Brown University
  • EVENT Study 329 — Clinical trial of paroxetine in adolescents
  • ORG Paroxetine — SSRI antidepressant drug (trade names Paxil, Seroxat)
  • ORG SmithKline Beecham — Sponsor of Study 329, pharmaceutical company
  • ORG GlaxoSmithKline — Successor to SmithKline Beecham
  • ORG Brown University — Academic institution where Keller was a professor emeritus

OPEN QUESTIONS — PENDING LEADS

  • Are there any publicly available email exchanges or internal communications from Martin Keller regarding Study 329's drafting or publication?
  • Did Martin Keller receive direct financial incentives or payments from SmithKline Beecham/GlaxoSmithKline specifically tied to the favorable publication of Study 329?
  • Have any co-authors of the original Study 329 paper made statements about Martin Keller's involvement in the publication process or awareness of the data discrepancies?
  • Are there any declassified pharmaceutical industry documents or court records that detail the editorial process for Study 329's publication and Martin Keller's role?
  • What specific training or background did Martin Keller have in statistical analysis of clinical trial data at the time of Study 329's publication?

EVIDENCE — CAPTURED SOURCES

  1. [WEB] https://en.wikipedia.org/wiki/Study_329 [archived]
    Study 329 was a clinical trial which was conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating 12- to 18-year-olds diagnosed with major depressive disorder.
  2. [WEB] https://www.medienanstalt-nrw.de/fileadmin/user_upload/NeueWebsite_0120/Themen/Desinformation/Leibnitz-Institute_LFMNRW_StudyDisinformation.pdf [archived]
    The overview on understandings and types of disinformation indicates that two central criteria appear in virtually all definitions: A statement is partially or ...
  3. [WEB] https://en.wikipedia.org/wiki/Martin_Keller_(psychiatrist)
    Keller's article concluded that paroxetine was "generally well tolerated and effective for major depression in adolescents." [3] In fact, study 329 indicated otherwise for both efficacy and safety in treating teenagers, showing an increase in suicidality and emotional lability.
  4. [WEB] https://pmc.ncbi.nlm.nih.gov/articles/PMC9815531/ [archived]
    The study's main contribution is to explore creativity as a potential mediator for leadership–organizational innovation. Keywords: leadership role, ...
  5. [WEB] https://en.wikibooks.org/wiki/Professionalism/Martin_Keller,_SmithKline_Beecham,_and_Study_329 [archived]
    Study 329 is a clinical trial testing the efficacy of Paroxetine (an established adult antidepressant known by the trade names Paxil and Seroxat) for major depression in adolescents. SmithKline Beecham (later GlaxoSmithKline) owned the patent for Paroxetine and hoped Study 329 wo…
  6. [WEB] https://www.pedocs.de/volltexte/2023/26652/pdf/Seitz_et_al_2023_International_perspectives.pdf [archived]
    There is: ▫ An educational justification: the requirement for schools to educate all children together means that they have to develop ways of teaching that.
  7. [WEB] https://retractionwatch.com/2025/10/16/controversial-paxil-study-329-earns-expression-of-concern-after-critic-sues-publisher/ [archived]
    Martin B. Keller, first author on the original paper and a professor emeritus of psychiatry and human behavior at Brown University in Providence, Rhode Island, did not return messages seeking comment. Critics of Study 329 called the expression of concern a long time coming. "It's…
  8. [REDDIT] https://www.reddit.com/r/mrballen/comments/1ifq0t2/2025_mega_thread_story_suggestions/ [archived]
    2 Feb 2025 · He is a storyteller of the strange, dark and mysterious. He would kidnap them, lock them up & torture them for days, making sure they couldn't ...
  9. [REDDIT] https://www.reddit.com/r/AdvocacTodayUSA/ [archived]
    329 : Judge rules transgender teen can temporarily play on girls' soccer team amid new law. 330 : Confusion swirls following court order on Biden's SAVE plan.
  10. [REDDIT] https://www.reddit.com/r/a:t5_t3g97/comments/a8w299/archive_original_posted_on_june_03_2015/ [archived]
    23 Dec 2018 · magazine sizes for "assault" weapons. US diplomats to steal DNA samples from other UN diplomats
  11. [WEB] https://www.researchgate.net/publication/23258838_Industry-Sponsored_Ghostwriting_in_Clinical_Trial_Reporting_A_Case_Study [archived]
    Study 329 for paroxetine pediatric use was negative for efficacy and positive for harm. Yet the ghostwritten publication from this study concluded that ...

CROSS-REFERENCE

Study 329: Paroxetine Clinical Trial Data Suppression and Publication Bias — SHARES-EVENT (OUTGOING)STUDY 329: PAROXETINE CLI…Martin Keller's Role and Statements in Study 329 Paroxetine TrialMARTIN KELLER'S ROLE AND ST…THIS FILESHARES-EVENT